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Recently, anandamide (AEA) analogues have been well recognized for its potent neuroprotective effects
in counteracting the deterioration of Alzheimer's disease (AD) brains through multiple pathological
processes. In our previous studies, dipotassium N-stearoyltyrosinate (NSTK), an AEA analogue synthe-
sized by our laboratory was reported to exert signiﬁcant efﬁcacy through multiple interventions. Within
this study, the amyloid precursor protein (APP)SWE/presenilin-1 (PS1)M146V/TauP301L mouse (3Tg-AD)
model was used to explore further the neuroprotective effects of NSTK and its underlying mechanisms.
NSTK could increase spontaneous locomotor activity in the open ﬁeld and low anxiety-like behavior in
the elevated plus maze, and improve the spatial memory deﬁcits in the Morris water maze. The
biochemical analysis suggested that NSTK could decrease Ab42 deposition, abnormal tau aggregation, and
the expressions of p-APP Thr668, PS1 and p-tau Ser202/Thr205 in the hippocampus of 3Tg-AD mice.
Consistently, NSTK could reduce the level of malondialdehyde, increase the activity of superoxide dis-
mutase and catalase. Up-regulation of Bcl-2, and down-regulation of BAX, caspase-3 and inﬂammatory
cytokines also occurred in the hippocampus of 3Tg-AD mice after treatment with NSTK. Thus, NSTK
could intervene in multiple pathological processes of AD and would be a drug candidate against AD.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer's disease (AD), a neurodegenerative disorder char-
acterized by progressive cognitive dysfunction and behavioral
impairment has become a major threat to human health. In AD
brain, presenilin-1 (PS1) processes the amyloid precursor protein
(APP) to generate amyloid (Ab) peptides: as a matter of fact, clinical
features of AD are manifested morphologically by excessive accu-
mulation of extracellular aggregation of Ab peptides in the form of
amyloid plaques, and intracellular neuroﬁbrillary tangles (NFTs)
composed of perphosphorylated tau (1). Experimental evidence
indicates that Ab deposition and tau hyperphosphorylation trigger
oxidative stress and inﬂammation, which lead to glial cell prolif-
eration and eventually neuronal loss (2). Although numerousang), luyangssmu@163.com
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).therapeutic agents aiming at the speciﬁc pathological process
(3e5) have been developed, few of them are efﬁcacious in vivo
because of ignoring the integrity of pathogenesis and the relevance
of multiple biological processes of AD and their applications in AD
are limited. Therefore, it is imperative to ﬁnd novel agents against
AD via multiple pathways of intervention.
In damaged brain tissues, the endocannabinoid system (ECS)
which consists of endocannabinoid (anandamide, AEA), its re-
ceptors and catabolic enzymes (e.g. fatty acid amide hydrolase,
FAAH) regulates multiple pathological pathways in the central
nervous system and has emerged as a potential target for the
neuroprotection. It has been reported that the inhibitors of
FAAH can decrease AEA hydrolysis and elevate AEA levels
correspondingly, which are associated with anti-oxidative, anti-
apoptotic and anti-inﬂammatory activities (6e8). Dipotassium
N-stearoyltyrosinate (NSTK, Fig. 1), an AEA analog, was devel-
oped in our laboratory and is a promising neuroprotective
candidate against stroke currently under preclinical studies in
China. NSTK could ameliorate cognitive dysfunction induced by
chronic cerebral hypoperfusion/global cerebral ischemia in rats/nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Chemical structure of NSTK.
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involve the inhibition of FAAH and the subsequent indirect
activation of cannabinoid receptors (12), which ﬁnally improves
inﬂammation, oxidative stress and glutamate-induced toxicity
and cell viability (9e11). The above researches showed that
NSTK has good neuroprotective effects through ECS-mediated
multiple pathways.
Since inﬂammation, oxidative stress and glutamate-induced
apoptosis are the common pathological characteristics in stroke
as well as in AD (13e15) and NTSK had the potential to improve the
pathological processes in cerebral ischemia model, NSTK might be
also effective in AD treatment. Indeed, we have demonstrated the
effects of NSTK against Ab-induced toxicity on primary cortical
neurons (12). It is interesting to observe the anti-AD effect of NSTK
based on the animal model, especially on the triple-transgenic
mouse model of AD (3Tg-AD mice) which over-expresses hu-
man APP, PS1 and tau mutations. Since 3Tg-AD mice not only
progressively develop the typical pathological features and show
behavioral impairments, but also mimic many aspects of human AD
(16), it is of great clinical signiﬁcance to validate the efﬁcacy of
NSTK on the model of AD.
In the present study, 3Tg-AD mice were used to conﬁrm the
efﬁcacy and mechanisms of NSTK in the treatment of AD. We
ﬁrst observed the animal behaviors as well as typical patho-
logical features of the mice to evaluate the efﬁcacy of NSTK
against AD. Then, the key factors related to oxidative stress,
inﬂammation and apoptosis in the transgenic mice were
investigated to conﬁrm the underlying mechanism of NSTK. In
accordance with our previous observations in neuron (12), NSTK
obviously improves behaviors and pathological features in
3Tg-AD mice. Moreover, we found the mechanisms involved
not only the improvement of glutamate-induced toxicity, which
we have conﬁrmed recently (9), but the decrease of inﬂamma-
tory response, oxidative stress and the inhibition of apoptosis
via ECS indirect activation.
2. Materials and methods
2.1. Chemicals
NSTK with purity over 98% was prepared in our laboratory and
its structure was conﬁrmed by 1H NMR and 13C NMR. NSTK and
Piracetam purchased from Sigma Chemical Co. (St. Louis, MO, USA)
were dissolved in sterilized water and stored at 20 C.
2.2. Animals
The 3Tg-AD mice were obtained by crossing heterozygous
APPswe/PS1dE9 double transgenic mice (Jackson Laboratory, Bar
Harbor, ME, USA) with heterozygous P301L tau transgenic mice
(Taconic Labs, Germantown, N.Y.). The wild male C57BL/6J mice
(Shanghai SLAC Laboratory Animal CO., Ltd, Shanghai, China) and
3Tg-AD mice were maintained in a controlled environment at
25 ± 1 C with a 12/12 h light-dark cycle. The experimental pro-
tocols were performed according to the Guidelines for Animal
Experimentation of Shanghai Jiao Tong University.2.3. Experimental treatment
50 male 3Tg-AD mice (9-month-old at the start of the study)
were randomly divided into ﬁve groups (each n¼ 10): the 3Tg-AD
group, three groups of 3Tg-AD mice treated with 15, 30 and
45 mg/kg NSTK respectively, and the 3Tg-AD group treated with
piracetam (100 mg/kg) as the positive control. Each mouse was
administrated orally in a volume of 0.1 mL per 10 g weight for 2
months. The wild mice were used for the control group (n ¼ 10).
Experimental groups and the wild group received an equal volume
of NSTK and distilled water, respectively. The animals were
behaviorally tested after 2 months of treatment. The behavioral
tests were carried out in the following order: open ﬁeld testing
(OFT), elevated plus-maze (EPM), Morris water maze (MWM). The
animals were sacriﬁced and the brains were removed from the
skulls after the animal experiment. Half of the brain was used for
immunoﬂuorescence, and the rest for western blotting and
enzyme-linked immunosorbent assay (ELISA). Since the hippo-
campus is themajor part of learning andmemory function, we used
the tissue homogenates of the hippocampus for western blotting
and ELISA in this study.
2.4. OFT
The OFT was used to assess general locomotor activity. Each
mouse was placed in the center of the open ﬁeld apparatus
(50  50  38 cm) equipped with a video-tracking system and
allowed to explore the apparatus for 5 min with the experimenter
out of view. The total distance moved in the arena was recorded.
2.5. EPM
The apparatus (50 cm height from ﬂoor) is consisted of two open
arms (30  5 cm) and two enclosed arms (30  5  15 cm) and is
used to measure anxiety-like behaviors of the mouse. Each mouse
was placed in the central section facing an open arm and was
allowed to explore the maze for 5 minwith the experimenter out of
view. The time spent in the open arms was recorded using a video
camera.
2.6. MWM
The MWM is consisted of a circular pool (1.8 m in diameter)
ﬁlled with water (24 ± 1 C) and is surrounded with curtains to
avoid environmental distraction. It was used to assess the spatial
learning and memory. The target quadrant contained an escape
platform (9 cm in diameter) which was submerged 1 cm below the
surface of water in the center of one quadrant. During the training,
each mouse was given 4 trials per day for 5 consecutive days.
During each trial, the mouse was placed into the pool facing the
wall at one random quadrant and allowed 60 s to locate the plat-
form. Any animal who did not locate the platform was guided and
placed on the platform for 30 s. On the 6th day, probe trials were
carried out in which the platform was removed and the mice were
given 60 s to search for the target quadrant. The escape latency, the
time spent in the target quadrant and searching strategy were
recorded by the video-tracking system.
2.7. Immunohistochemistry
The 3Tg-AD mice were anesthetized with pentobarbital,
perfused with saline, and then perfused with 4% paraformaldehyde
in 0.1 M phosphate-buffered saline (PBS), pH 7.4. The brains were
removed from the skulls, ﬁxed in 4% paraformaldehyde for 24 h and
then transferred into PBS containing 30% sucrose. Each brain was
S. Liu et al. / Journal of Pharmacological Sciences 132 (2016) 92e9994sectioned in the coronal plane at an instrument setting of 10 mm.
Free ﬂoating sections were washed with PBS three times before
being permeabilized with 0.3% Triton X-100 for 10 min, blocked
with 3% bovine serum albumin (BSA) diluted in PBS for 1 h and then
incubated overnight at 4 C with the following primary antibodies:
rabbit anti-Ab42 (1:200, Abcam, Cambridge, Cambs, UK) and mouse
anti-202/205 phosphorylated tau (AT8, 1:100, Life Technologies,
Carlsbad, CA, USA). After several washes in PBS, the slides were
incubated for 1 h at room temperature with the secondary anti-
body: DyLight 594 goat anti-rabbit IgG (1:500, Thermo Scientiﬁc,
Rockford, IL, USA) in the dark. 40, 6-diamidino-2-phenylindole
(DAPI, 1:500, Thermo Scientiﬁc) was used to detect cell nuclei. Af-
ter being washed three times in PBS, the sections were then
mounted on charged slides for immunoﬂuorescence detection us-
ing an Olympus microscope with DP-70 software. The imaging data
were analyzed and quantiﬁed using Image pro-plus version 6.0.
2.8. Western blotting analysis
The frozen brains were lysed with an ice-cold RIPA lysis buffer
(Beyotime Institute of Biotechnology, Jiangsu, China) with complete
protease inhibitor cocktail and phosphatase inhibitor cocktail
(Roche, Indianapolis, IN, USA). Lysates were centrifuged at 12,000 g
for 20 min at 4 C. The supernatants were collected and total pro-
tein concentrations were estimated using the Bradford method by
means of the protein assay kit (Beyotime Institute of Biotech-
nology). Total proteins were denatured at 100 C for 8 min and
60 mg proteins per lane were separated on 10% SDS-polyacrylamide
gel and electro-transferred onto a polyvinylidene diﬂuoride mem-
brane (Millipore, Bedford, MA, USA). Membranes were blocked
with 5% BSA in Tris-buffered salinewith 1% Tween-20 (TBST) for 2 h
at room temperature and then incubated overnight at 4 C with the
following primary antibodies: rabbit anti-interleukin-1b (IL-1b),
rabbit anti-APP Thr668, rabbit anti-tumor-necrosis-factor-a (TNF-
a), rabbit anti-bcl-2 and anti-bax (1:1000, Life Technologies); rabbit
anti-PS1 (1:2000, Life Technologies); rabbit anti-interleukin-6 (IL-
6) andmouse anti-caspase-3 (1:1000, Abcam), mouse anti-202/205
phosphorylated tau (AT8, 1:100). GAPDH (1:8000, Life Technolo-
gies) was used as a loading control. Membranes were washed with
TBST three times for 10 min and then incubated in the secondary
antibody, anti-rabbit or anti-mouse IgG HRP-linked antibody
(1:4000, Life Technologies) for 2 h. The blotted protein bands were
visualized by chemiluminescence detection reagents (Amersham,
Arlington Heights, IL, USA). Optical densities were obtained using a
software (Bio-Rad Laboratory, USA) and the protein levels were
normalized to GAPDH.
2.9. ELISA
Brain hemispheres were homogenized in ice-cold PBS contain-
ing 5 M guanidine hydrochloric acid and 1  protease inhibitorFig. 2. NSTK improved the behaviors of the 3Tg-AD mice in the OFT and EPM (n ¼ 10). (A)
activity, which of the 3Tg-AD mice was less than that of the wilds. NSTK could signiﬁcantly
the open arms) of mice was evaluated in the EPM. The 3Tg-AD mice spent more time in
3Tg-AD mice. Values are reported as the mean ± S.E.M. *P < 0.05 and **P < 0.01 vs. 3Tgmixture (pH 8.0) (17). The levels of Ab42 were quantiﬁed using
ELISA kits according to the manufacturer's instruction (Invitrogen,
Camarillo, CA, USA) and expressed as ng/g protein. The oxidant-
antioxidant status of the brains was assessed by determining the
activities of superoxide dismutase (SOD), catalase (CAT), gluta-
thione peroxidase (GPx) and the concentration of malondialdehyde
(MDA). The measurement procedures were performed following
the manufacturer's instruction using commercial kits (Beyotime
Institute of Biotechnology).
2.10. Statistical analyses
SPSS statistical software 16.0 for windows was used. All results
were evaluated by using one-way ANOVA and Dunnett's multiple
range tests. All values were expressed as mean ± standard error of
the mean (S.E.M). Statistical signiﬁcance was assumed if P < 0.05.
3. Results
3.1. NSTK improved the behaviors of 3Tg-AD mice in the OFT, EPM
and MWM
The total traveled distance of mice in the OFT was evaluated as
spontaneous locomotor activity (Fig. 2A), which of the 3Tg-AD
mice was less than that of the wilds. NSTK could signiﬁcantly in-
crease that of the 3Tg-AD mice. The anxiety-related behavior (the
time spent in the open arms) of mice was evaluated in the EPM
(Fig. 2B). The 3Tg-AD mice (low anxiety) spent more time in the
open arms compared with the wilds. NSTK could signiﬁcantly
improve that of the 3Tg-AD mice.
The escape latency in MWM was evaluated per day for 5
consecutive days. The escape latency of the 3Tg-AD mice was
longer than that of the wilds. NSTK (30 and 45 mg/kg) reversed
these effects (Fig. 3A). The swimming time in the target quadrant
and the swimming track in the probe trial were evaluated to esti-
mate retention performance at the end of ﬁve-days-training period.
The swimming time in the target quadrant of the 3Tg-AD mice
was not longer than that of the wilds. NSTK (30 and 45 mg/kg)
reversed the effects (Fig. 3B). The swimming track of the 3Tg-AD
mice was in an inappropriate way for the platform and NSTK
resulted in fewer excursions in the target quadrant (Fig. 3C).
3.2. NSTK ameliorated Ab and tau pathology
The Ab42 deposition in the cortex and hippocampus of the 3Tg-
AD mice was signiﬁcantly higher than in the wilds, while NSTK (30
and 45 mg/kg) signiﬁcantly decreased the deposition. The amount
of Ab42 decreased from 27.86 ± 5.075 ng/g in the 3Tg-AD mice to
16.3 ± 2.941 ng/g (30mg/kg) and to 13.9 ± 3.782 ng/g (45 mg/kg) in
the NSTK groups, suggesting that NSTK decreased the level of Ab42
in the brain of the 3Tg-AD mice (Fig. 4). As shown in Fig. 4B, theThe total traveled distance of mice in the OFT was evaluated as spontaneous locomotor
increase that of the 3Tg-AD mice. (B) The anxiety-related behavior (the time spent in
the open arms compared with the wilds. NSTK could signiﬁcantly improve that of the
-AD mice.
Fig. 3. NSTK improved the behaviors of the 3Tg-AD mice in the MWM (n ¼ 10). (A) The escape latency of the 3Tg-AD mice was longer than that of the wilds. NSTK (30 and
45 mg/kg) reversed these effects. (B) The swimming time in the target quadrant of the 3Tg-AD mice was not longer than that of the wilds. NSTK (30 and 45 mg/kg) reversed the
effects. (C) The swimming track of the 3Tg-AD mice was in an inappropriate way for the platform and NSTK resulted in fewer excursions in the target quadrant. Values are reported
as the mean ± S.E.M. *P < 0.05 and **P < 0.01 vs. 3Tg-AD mice.
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signiﬁcantly increased compared to the wilds, NSTK could signiﬁ-
cantly reduce that of the 3Tg-AD mice, which were unanimous
with the results of Fig. 4CeE.
The intensity of AT8, which recognizes tau phosphorylated at
both Ser202 and Thr205 in the hippocampus was signiﬁcantly
higher in the 3Tg-ADmice than in the wilds (Fig. 5A and C), which
was similar with the results of western blotting (Fig. 5B and D).
NSTK treatment (45 mg/kg) signiﬁcantly reversed the phenomena.
3.3. NSTK attenuated oxidative stress
Oxidative stress is an important factor for the progression of AD
(14). The antioxidant enzymes play pivotal roles against excess free
radicals. The level of MDA is routinely used to reﬂect the extent of
cell membrane damage resulting from attacks by oxygen-radicals.
In the brains of the 3Tg-AD mice, the content of MDA signiﬁ-
cantly increased and the activities of CAT, SOD and GPx showed a
marked decrease compared with those of the wilds, whereas NSTK
(30 and 45 mg/kg) only increased the activities of CAT and SOD in
the hippocampus of 3Tg-AD mice (Fig. 6) and the 3Tg-AD mice
treated with NSTK revealed a non-signiﬁcant increase in the ac-
tivities of GPx (data not shown).
3.4. NSTK blunted inﬂammatory and apoptotic responses
Ab deposition and tau hyperphosphorylation promote inﬂam-
mation by stimulating the release of inﬂammatory cytokines (18).The levels of IL-6, IL-1b and TNF-a in the 3Tg-AD mice were
signiﬁcantly higher than in the wild mice. Intervention of NSTK (30
and 45 mg/kg) decreased the levels of IL-6, IL-1b and TNF-a in the
3Tg-AD mice (Fig. 7). The Bcl family and the caspase family are
well-known with respect to the apoptosis (19). The expressions of
Bcl-2 in the 3Tg-AD mice were dramatically decreased compared
to thewilds, whereas that of Bax increased. The expressions of Bcl-2
and Bax in the NSTK groups were reversed (Fig. 8AeC). Further-
more, the expression of the executioner caspase-3 involved in the
ultimate of apoptosis was signiﬁcantly increased in the 3Tg-AD
mice compared with the wilds and in the NSTK groups a signiﬁcant
decrease in caspase-3 protein expression was observed (Fig. 8A,D).4. Discussion
The discovery and application of a candidate intervening in
multiple pathological processes is a novel strategy for AD treat-
ment. The inhibitors of FAAH could improve multiple pathological
processes (oxidative stress, inﬂammation, apoptosis, etc.) and
showed benign effects (6e8). Preclinical studies of NSTK had
demonstrated its biological activities similar to endocannabinoids
based on the cellular and animal experiments (9e12). NSTK as an
inhibitor of FAAH responsible for AEA inaction is different from
cannabinoid receptor agonists. The application of a cannabinoid
receptor agonist would result in broad cannabinoid-like effects
including therapeutic effects in the damaged tissue and side effects
in the normal tissue (20). However, the application of NSTK resulted
in cannabinoid-like effects only in the damaged tissue, but had no
Fig. 4. NSTK ameliorated Ab pathology in the brains of the 3Tg-AD mice (n ¼ 6). (A) The Ab42 deposition (red) in the cortex and hippocampus of the 3Tg-AD mice was signiﬁcantly
higher than in the wilds, while NSTK (30 and 45 mg/kg) signiﬁcantly decreased the deposition. Cell nuclei were stained with DAPI (blue). Scale bars represented 100 mm. (B) The
expressions of p-APP Thr668 and PS1 in the 3Tg-AD mice were signiﬁcantly increased compared to the wilds, NSTK could signiﬁcantly reduce that of the 3Tg-AD mice. GAPDH was
used as a loading control. (C) Number of Ab42 plaques in the cortex. (D) Number of Ab42 plaques in the hippocampus. (E) NSTK decreased the level of Ab42 in the brain of the 3Tg-AD
mice. (F and G) Quantiﬁcation of expression of p-APP Thr668 and PS1. Values are reported as the mean ± S.E.M. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. 3Tg-AD mice.
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tissue and in a resting state in the normal tissue. The facts that NSTK
showed curative effects on cerebral ischemia and that the patho-
logical processes in cerebral ischemia are similar to those of AD
promoted us to study the feasibility of NSTK in the treatment of AD.
In this study we evaluated NSTK's neuroprotective effects and
veriﬁed the mechanisms based on an AD animal model, then
revealed its value for AD treatment. Piracetam as a nootropic drug
could improve the function of mitochondria, inhibit the patholog-
ical processes of oxidative stress, inﬂammation and apoptosis, and
has been widely used in treatment of older patients with dementia
or cognitive problems (21e23). Piracetam as a positive drug is also
used in the studies (24,25).
The traditional AD animal models (26) show some learning and
memory impairments, but do not or only partly mimic the path-
ological features of AD and therefore are limited in anti-AD drug
research. The transgenic mice accurately mimic the regional and
speciﬁc pathological features of AD and provide a guarantee forthe study of AD. To comprehensively evaluate the effects of NSTK
on AD, we used the 3Tg-AD mice in the study. Although the 3-
month-old transgenic mice were used in a few reports to eval-
uate the effects of compounds in treating AD (3), in the present
study the 9-month-old transgenic mice were used, which were
more closely resemble clinical pathological features of AD (27). To
understand the effects of NSTK on transgenic mice, we assessed
three indexes related to cognitive and non-cognitive behaviors of
transgenic mice: autonomic activity (OFT), anxiety level (EPM)
and the ability of learning and memory (MWM). In the NSTK
groups, the autonomic activities of transgenic mice have been
enhanced and the low anxiety (disinhibitory tendencies) of
transgenic mice have been improved, indicating the mice are
afraid of the danger (28,29). The improvement of the abnormal
behavior might be associated with high emotion induced by brain
activation which also improved the dysfunction of learning and
memory of mice (30). Ab deposition and tau hyper-
phosphorylation could induce animal behavior disorders (3).
Fig. 5. NSTK ameliorated tau pathology in the hippocampus of the 3Tg-AD mice (n ¼ 6). (A) The aggregation of NFTs (red) in the hippocampus of the 3Tg-AD mice was
signiﬁcantly higher than in the wilds, while NSTK (30 and 45 mg/kg) signiﬁcantly decreased the aggregation. Cell nuclei were stained with DAPI (blue). Scale bars represented
100 mm. (B) The expressions of p-tau Ser202/Thr205 in the 3Tg-AD mice were signiﬁcantly increased compared to the wilds, NSTK could signiﬁcantly reduce that of the 3Tg-AD
mice. GAPDH was used as a loading control. (C) Number of NFTs in the hippocampus. (D) Quantiﬁcation of p-tau Ser202/Thr205 expression. Values are reported as the mean ± S.E.M.
*P < 0.05, **P < 0.01 and ***P < 0.001 vs. 3Tg-AD mice.
Fig. 6. NSTK attenuated oxidative stress in the brains of the 3Tg-AD mice (n ¼ 6). The activities of CAT (A) and SOD (B) showed a marked decrease and the content of MDA (C)
signiﬁcantly increased compared with the wilds, whereas NSTK (30 and 45 mg/kg) reversed the above phenomena. Values are reported as the mean ± S.E.M. *P < 0.05 and **P < 0.01
vs. 3Tg-AD mice.
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PS1 which could be resulted from inﬂammation, oxidative stress
and glutamate excitotoxicity (31e33) and reversed by the inter-
vention of multiple pathological pathways (2,34) and inhibited
the formation of NFTs and the expression of p-tau, indicating that
NSTK alleviated two pathological characteristics from macro and
micro perspectives. The above mentioned results comprehen-
sively evaluated neuroprotective effects of NSTK from animal
behaviors and pathological features.
Ab deposition and tau hyperphosphorylation could activate
glial cells, then release a number of inﬂammatory mediators
which would further activate other glial cells, damage cellmembranes and cause inﬂammation and oxidative stress (2).
Accordingly, NSTK could signiﬁcantly reduce the release of in-
ﬂammatory cytokines, decrease the inﬂammatory cascade reac-
tion, and then improve the disorders of the central nervous
system. In the NSTK groups, the product of lipid peroxidation and
the activities of antioxidant enzymes were improved, consisted
with our previous observations in PC12 cells and on mice in
ischemia reperfusion injury (9,10). The treatment of 3Tg-AD
mice with NSTK reduced the level of MDA and increased the ac-
tivities of CAT and SOD but not that of GPx. The results might be
related to the inhibition of active microglia which generate reac-
tive oxygen species (35). Since the microglia-mediated oxidative
Fig. 7. NSTK attenuated inﬂammatory responses in the brains of the 3Tg-AD mice (n ¼ 6). (A) The protein expressions of IL-6, IL-1b and TNF-a in the 3Tg-AD mice were
signiﬁcantly higher than in the wild mice. Intervention of NSTK (30 and 45 mg/kg) decreased the levels of IL-6, IL-1b and TNF-a in the 3Tg-AD mice. GAPDH was used as a loading
control. (B, C and D) Quantiﬁcation of IL-1b, IL-6 and TNF-a. Values are reported as the mean ± S.E.M. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. 3Tg-AD mice.
Fig. 8. NSTK blunted apoptotic responses in the brains of the 3Tg-AD mice (n ¼ 6). (A) The expressions of Bcl-2 in the 3Tg-AD mice were dramatically decreased compared to the
wilds, whereas that of Bax and caspase-3 increased. The expressions of Bcl-2, Bax and caspase-3 in the NSTK groups were reversed. GAPDH was used as a loading control. (B, C and
D) Quantiﬁcation of Bcl-2, Bax and caspase-3. Values are reported as the mean ± S.E.M. *P < 0.05 and **P < 0.01 vs. 3Tg-AD mice.
S. Liu et al. / Journal of Pharmacological Sciences 132 (2016) 92e9998stress is a complicated process, the further studies are required to
elucidate the antioxidant mechanisms of NSTK.
Ab deposition, NFTs, inﬂammation, and oxidative stress could
activate apoptotic pathways (36e38). NSTK could obviously regulate
the level of Bcl-2 and Bax, and reduce the expression of Caspase-3,
which were further conﬁrmed our previous immunohistochemicalobservations that NSTK could improve the morphology of apoptosis
in the brain of mice (10). The current observations suggested that
NSTK reduced neuronal apoptosis in brain tissue from both regula-
tion and execution of apoptosis from the protein levels.
In damaged brain tissue, ECS is capable of activating distinct
signaling pathways in response to different pathogenic events
S. Liu et al. / Journal of Pharmacological Sciences 132 (2016) 92e99 99through activating cannabinoid receptors and has been demon-
strated to modulate the main pathological processes, including
neuroinﬂammation, excitotoxicity and oxidative stress, and then
reduce the secondary injuries (6e8). NSTK could regulate ECS by
inhibition of FAAH, therefore, it would be a good candidate for the
treatment of AD.Conﬂicts of interest
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